assessing the main drivers of cost of care and model the impact of oral targeted therapies and immunotherapies on the cost of lung cancer care.
Background: The competency in video-assisted thoracoscopic (VATS) lobectomy is expected to be achieved after surgeons practiced 30 to 50 cases according to previous reports. Does single port video-assisted thoracoscopic (SPVATS) lobectomy have a steeper learning curve and being harder to perform correctly, leading to long development times and high defect rates? Method: From January 2014 to February 2017, 8 individual surgeons (3 were novices, 5 were pioneers in SPVATS surgery) submitted their cases chronologically to evaluate the learning curve of SPVATS lobectomy. Propensity score match between two groups and cumulative sum(-CUSUM) method were used to explore evolution of learning curve Result: Before propensity-score matching, a total of 356 cases were included (93 in junior consultant group (group A), 263 in senior consultant group (group B). There were no differences between the groups in operative time, conversion rate, postoperative complication rate, 30 and 90 day mortality rate. After propensity-score matching, operative time was longer in group A (214.33±62.18 v.s 183.62±61.25 mins, p¼0.001). 2-year overall survival rate was similar among two groups (p¼0.409). Competency was reached after junior surgeon completed 30th case of SPVATS lobectomy. Conclusion: SPVATS lobectomy is safe for the novice surgeon who wants to adopt this new surgical approach under well-developed training program. The learning curves for competence in SPVATS lobectomy is similar to VATS lobectomy in our series. Keywords: Single port VATS, learning curve, novice Circulating tumor DNA (ctDNA) is promising as a minimally-invasive liquid biopsy for testing gene alterations and monitoring personalised treatment strategies. Because of its high expense, translation of the sensitive and accurate next generation sequencing (NGS) into routine cancer care has been slow. Method: We retrospectively reviewed 60 advanced NSCLC pts who were performed gene test prior to treatment using tissue by ARMS. Blood collections (10ml K2-EDTA) were performed after disease progression and analysed by NGS using a 10-gene panel (EGFR, KRAS, BRAF, HER2, PIK3CA, ALK, ROS1, RET, MET and TP53). We evaluated the significance of the outcome of panel testing by NGS in guiding the subsequent treatment in clinical practice. Result: Among 60 NSCLC pts, 39 were male, 28 were neversmokers, and 56 were adenocarcinoma. ctDNA profiling detected alterations in 50 pts (83%). TP53 (53%), EGFR (48%) and KRAS (15%) were the most common abnormalities detected. Additionally, MET (8%), ALK (3%), HER2 (3%) and PIK3CA (2%) mutations were detected, respectively. Sensitizing mutations were detected in 22 pts (37%) prior to treatment using tissue by the method of ARMS, including 20 EGFR mutations and 2 ALK fusions, and all pts received tyrosine kinase inhibitor (TKI) as first-line therapy. Among 20 EGFR mutant pts, T790M mutation was detected in 9 pts (45%), KRAS mutation was detected in 4 pts (20%), and TP53 mutation was detected in 12 pts (60%), while MET amplification was found in 1 pt (5%). 1 KRAS mutation and 1 TP53 mutation were detected in 2 ALK eTKI resistant pts, respectively. 28 pts (47%) reported as tissue negative had a positive liquid biopsy, including 4 MET 14 exon skipping mutations, 2 EGFR 19 DEL, 4 EGFR L858R and 1 EGFR L861Q, and 2 EGFR T790M mutations. The mutation abundance is all below 1%, except 2 EGFR 19 DEL and 4 L858R. Ten pts received TKIs; 2 got parcial responses, 5 stable diseases and 3 progressive disease. Conclusion: ctDNA can be used as a 'liquid biopsy' for molecular profiling of NSCLC pts, and NGS, as a highly sensitive method to detect mutations with low mutation abundance, can provide more chances to pts to receive precise treatment. Background: Findings on computed tomography like tumor size, amount of consolidation and ground glass opacity, size of the solid component, maximum standardized uptake value by 18F-fluorodeoxyglucose positron emission tomography/CT and the ratio of the size of solid attenuation to the maximum tumor dimension (consolidation/ tumor [C/T] ratio) are predictive for pathologic subtypes and prognosis after resection. There are many number of study about clinical early stage lung cancer in terms of C/T ratio. We aimed to investigate prognostic value of C/T ratio and SUVmax among patients with pathological stage I lung adenocarcinoma Method: 258 patients were reviewed by using institution's records who had undergone surgery for early stage lung adenocarcinoma. Only patients with pathological stage I (T1a, T1b and T2a without lymph node metastasis) were included. Synchronous tumor, oligometastatic disease and history of other organ malignancy was
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